Several other brokerages have also issued reports on AGIO. Cowen reaffirmed a buy rating on shares of Agios Pharmaceuticals in a research note on Wednesday, March 13th. ValuEngine raised Agios Pharmaceuticals from a hold rating to a buy rating in a research note on Monday, April 1st. Svb Leerink raised Agios Pharmaceuticals from a market perform rating to an outperform rating and set a $80.00 price target on the stock in a research note on Friday, February 15th. Leerink Swann raised Agios Pharmaceuticals from a market perform rating to an outperform rating in a research note on Friday, February 15th. Finally, Piper Jaffray Companies cut their price target on Agios Pharmaceuticals to $100.00 and set an overweight rating on the stock in a research note on Thursday, February 14th. Five research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $97.86.
Shares of AGIO stock opened at $59.72 on Friday. The firm has a market cap of $3.50 billion, a PE ratio of -9.90 and a beta of 2.38. Agios Pharmaceuticals has a 52 week low of $41.63 and a 52 week high of $99.82.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, February 14th. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.65) by $0.07. Agios Pharmaceuticals had a negative return on equity of 44.13% and a negative net margin of 366.61%. The business had revenue of $30.00 million for the quarter, compared to analyst estimates of $19.98 million. During the same quarter in the prior year, the firm posted ($1.81) earnings per share. The firm’s revenue for the quarter was up 200.0% compared to the same quarter last year. On average, research analysts expect that Agios Pharmaceuticals will post -6.73 EPS for the current fiscal year.
In other Agios Pharmaceuticals news, insider Scott Biller sold 3,000 shares of the stock in a transaction dated Friday, April 5th. The stock was sold at an average price of $67.71, for a total value of $203,130.00. Following the transaction, the insider now owns 29,511 shares of the company’s stock, valued at $1,998,189.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Christopher Bowden sold 10,000 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $64.16, for a total value of $641,600.00. The disclosure for this sale can be found here. Insiders sold 42,000 shares of company stock worth $2,765,530 in the last three months. Insiders own 3.02% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in AGIO. Quantamental Technologies LLC acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at about $28,000. Advisor Group Inc. lifted its stake in Agios Pharmaceuticals by 33.1% in the fourth quarter. Advisor Group Inc. now owns 1,195 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 297 shares during the period. ETF Managers Group LLC lifted its stake in Agios Pharmaceuticals by 15.7% in the fourth quarter. ETF Managers Group LLC now owns 1,592 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 216 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Agios Pharmaceuticals by 14.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,457 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 430 shares during the period. Finally, SG Americas Securities LLC acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at about $188,000. 98.77% of the stock is currently owned by hedge funds and other institutional investors.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Further Reading: Price to Earnings Ratio (PE), For Valuing Stocks
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.